218 patents
Utility
Fused pyrimidine derivatives as A2A/A2B inhibitors
16 Jan 24
Xiaozhao Wang, Heeoon Han, Matthew S. McCammant, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Le Zhao
Filed: 27 Jan 21
Utility
Heterocyclic compounds as immunomodulators
16 Jan 24
Kaijiong Xiao, Fenglei Zhang, Liangxing Wu, Wenqing Yao
Filed: 19 Nov 20
Utility
Benzothiazole compounds and uses thereof
9 Jan 24
Joshua Hummel, Oleg Vechorkin, Alexander Sokolsky, Qinda Ye, Kai Liu, Wenqing Yao
Filed: 16 Nov 20
Utility
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
9 Jan 24
The present application provides dihydropyrido[2,3-d]pyrimidone inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Alexander Sokolsky, Liangxing Wu, Wenqing Yao
Filed: 10 Jun 21
Utility
Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
9 Jan 24
This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3′-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.
Dengjin Wang, Daniel Carper, Zhongjiang Jia, Bo Shen, Joseph A. Sclafani, Robert Wilson, Jiacheng Zhou, Osama Suleiman, Mark Wright
Filed: 5 Nov 21
Utility
Heterocyclic compounds as immunomodulators
9 Jan 24
Neil Lajkiewicz, Liangxing Wu, Wenqing Yao
Filed: 22 Nov 22
Utility
Salts and crystalline forms of a PD-1/PD-L1 inhibitor
9 Jan 24
This application relates to solid forms and salt forms of the PD-1/PD-L1 inhibitor 4,4′-(((((2,2′-dichloro-[1,1′-biphenyl]-3,3′-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid), including processes of preparation thereof, where the solid forms and salt forms are useful in the treatment of various diseases including infectious diseases and cancer.
Zhongjiang Jia, Shili Chen, Yi Li, Timothy Martin, Bo Shen, Naijing Su, Jiacheng Zhou, Qun Li
Filed: 10 Nov 20
Utility
Substituted tricyclic compounds as FGFR inhibitors
12 Dec 23
The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
Liangxing Wu, Colin Zhang, Chunhong He, Liang Lu, Wenqing Yao
Filed: 2 Jun 21
Utility
Imidazopyridazine compounds and uses thereof
12 Dec 23
Jun Pan, Yu Bai, Liangxing Wu, Wenqing Yao
Filed: 10 Jun 21
Utility
JAK1 pathway inhibitors for the treatment of cytokine-related disorders
5 Dec 23
This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating cytokine-related diseases or disorders such as cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and CAR-T-cell-related encephalopathy syndrome (CRES).
Michael O'Neill Montgomery, Ahmad Naim, Susan Snodgrass
Filed: 19 Jul 21
Utility
Combination therapy for treatment of myeloproliferative neoplasms
5 Dec 23
The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a BET protein inhibitor, 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-1,4-benzoxazin-3(4H)-one, wherein the combination is unexpectedly synergistic.
Matthew Stubbs, Phillip C. Liu
Filed: 2 Jun 21
Utility
Heterocyclylamines as PI3K inhibitors
21 Nov 23
Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Brent Douty, Song Mei
Filed: 18 Jul 22
Utility
Pyrazolopyridine compounds and uses thereof
24 Oct 23
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Oleg Vechorkin, Jun Pan, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Wenqing Yao
Filed: 7 Jan 21
Utility
Solid forms of an HPK1 inhibitor
17 Oct 23
The present invention relates to salt forms of the hematopoietic progenitor kinase 1 (HPK1) inhibitors N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-5-fluorophenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide and N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-4-(4-cyanopyridin-3-yl)phenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide, including methods of preparation thereof, where the compounds are useful in the treatment of HPK1 mediated diseases such as cancer.
Zhongjiang Jia, William Frietze
Filed: 25 Jun 21
Utility
Heterocyclic compounds as immunomodulators
17 Oct 23
Liangxing Wu, Jingwei Li, Wenqing Yao
Filed: 15 Feb 22
Utility
Process of preparing a PD-1/PD-L1 inhibitor
10 Oct 23
The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3′-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.
Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Yi Li, Qiyan Lin, Pingli Liu, Yongchun Pan, Timothy Martin, Bo Shen, Chongsheng Eric Shi, Naijing Su, Yongzhong Wu, Michael Xia
Filed: 5 Nov 21
Utility
Tricyclic urea compounds as JAK2 V617F inhibitors
10 Oct 23
The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Yanran Ai, Onur Atasoylu, Yu Bai, Joseph Barbosa, David M. Burns, Daniel Levy, Brent Douty, Hao Feng, Leah C. Konkol, Cheng-Tsung Lai, Xun Liu, Song Mei, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue
Filed: 1 Jul 21
Utility
Heterocyclic compounds as PI3K-γ inhibitors
3 Oct 23
Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri
Filed: 24 Jun 21
Utility
Bicyclic dione compounds as inhibitors of KRAS
26 Sep 23
Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds.
Taisheng Huang, Xiaozhao Wang, Wenqing Yao
Filed: 1 Oct 21
Utility
Tricyclic pyridone compounds as JAK2 V617F inhibitors
26 Sep 23
The present application provides tricyclic pyridone compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Kai Liu, Onur Atasoylu, Yu Bai, Andrew W. Buesking, Leah C. Konkol, Cheng-Tsung Lai, Song Mei, Jun Pan, Liangxing Wu, Wenqing Yao
Filed: 1 Jul 21